MSMaaike R. Schagen

Maaike R. Schagen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maaike R. Schagen has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Dennis A. Hesselink

    Department of Internal Medicine, Erasmus MC Transplant Institute University Medical Center Rotterdam The Netherlands

    3 shared publications
  • Brenda C. M. de Winter

    Department of Hospital Pharmacy, Erasmus MC University Medical Center Rotterdam Rotterdam The Netherlands

    2 shared publications
  • Brenda C.M. de Winter

    Rotterdam Clinical Pharmacometrics Group, Rotterdam, The Netherlands

    2 shared publications
  • Dennis A. Hesselink

    Department of Internal Medicine Division of Nephrology and Transplantation Erasmus MC Rotterdam The Netherlands

    2 shared publications
  • Maja Matic

    Department of Clinical Chemistry Erasmus MC, University Medical Center Rotterdam the Netherlands

    2 shared publications
  • Alina A. Constantinescu

    Department of Cardiology, Thorax Center, Cardiovascular Institute, Erasmus MC University Medical Center Rotterdam Rotterdam the Netherlands

    1 shared publication

Latest Publications

  • Open Access

    Tacrolimus Exposure is Associated with Acute Rejection in the Early Phase After Kidney Transplantation: A Joint Modeling Approach

    by Maaike R. Schagen, Alvaro Assis de Souza, Karin Boer, Jesse H. Krijthe, Rachida Bouamar, Andrew P. Stubbs, Dennis A. Hesselink, Brenda C.M. de Winter

    Background: Reports regarding the relationship between tacrolimus exposure and the risk of acute kidney allograft rejection are conflicting. This may be explained by the previous use of methodological approaches that disregarded important factors in the analysis of longitudinal measurements and time-to-event data. Therefore, in this study, joint models were used to investigate the relationship between repeated measurements of tacrolimus predose concentrations (C 0 ) and time to acute biopsy-proven acute rejection (BPAR). Methods: This was a post hoc analysis of a randomized controlled trial in which living-donor kidney transplant recipients (KTR) received either a standard, bodyweight-based or CYP3A5 genotype-based tacrolimus starting dose. Joint modeling was performed by coupling a mixed-effects model for tacrolimus C 0 with a Cox proportional hazards model for the risk of rejection. Only the first episode of rejection was considered. Results: A total of 229 KTRs were included, of whom the incidence of BPAR was 10.5% (n = 24 KTRs) in the first 3 months posttransplant. A total of 3069 tacrolimus measurements were available for the analysis. A joint model adjusted for recipient age and peak panel reactive antibodies demonstrated that tacrolimus C 0 was associated with risk of rejection. A 1-unit increase in the time-normalized area under the curve for logarithmically (log)-transformed C 0 represented a change of −2.65 in the log of the relative hazard (95% credible interval: −5.05 to −0.36, P = 0.022). Conclusions: A negative association between the cumulative effect of tacrolimus C 0 and BPAR was observed using joint modeling. This demonstrated that KTRs with lower tacrolimus exposure were at a higher risk of rejection.


  • Open Access

    The tacrolimus concentration‐to‐dose ratio is associated with kidney function in heart transplant recipients

    by Maaike R. Schagen, Teun B. Petersen, Boris C. A. Seijkens, Jasper J. Brugts, Kadir Caliskan, Alina A. Constantinescu, Brenda C. M. de Winter, Isabella Kardys, Dennis A. Hesselink, Olivier Manintveld

    Aim: Heart transplantation (HT) is frequently complicated by chronic kidney disease, of which tacrolimus‐related nephrotoxicity is an important cause. In kidney and liver transplant recipients, fast tacrolimus metabolism (defined as a low concentration‐to‐dose [C0/D] ratio), negatively affects kidney function. Here, the association between the C0/D ratio and kidney function in HT recipients was investigated.Methods: This was a retrospective study including 209 HT recipients who received an immediate‐release tacrolimus formulation. The C0/D ratio and kidney function (estimated glomerular filtration rate [eGFR]) were assessed at 3, 6, 12, 36 and 60 months post‐HT. Patients were categorized as fast, intermediate and slow metabolisers, depending on their individual median C0/D ratio as calculated over the follow‐up period. A linear mixed‐effects model analysis was performed, in which the time‐varying eGFR was the dependent variable.Results: The distribution of the individual median C0/D ratios ranged from 0.41 to 8.9 ng/mL/mg. At baseline, patients' kidney function was comparable. In the multivariable linear mixed‐effects model, fast metabolisers (C0/D ratio ≤1.53) had a significantly lower eGFR compared to slow metabolisers (C0/D ratio >2.27) (−6.8 mL/min/1.73 m2, 95% CI −11.2, −2.4, p = 0.002). This association was confirmed when utilizing the individual median C0/D ratio as a continuous variable: for each 1 unit increase in the C0/D ratio there was a 2.8 mL/min/1.73 m2 (95% CI 1.0, 4.5) increase in eGFR (P = 0.002).Conclusion: Fast tacrolimus metabolism is significantly associated with worse kidney function in HT recipients in the first 5 years post‐HT when compared to recipients with intermediate and slow tacrolimus metabolism.


  • Prediction of the Intra‐T Lymphocyte Tacrolimus Concentration after Kidney Transplantation with Population Pharmacokinetic Modeling

    by Suwasin Udomkarnjananun, Maaike R. Schagen, Helena Volarević, Daan van de Velde, Marjolein Dieterich, Maja Matic, Carla C. Baan, Marlies E. J. Reinders, Brenda C. M. de Winter, Dennis A. Hesselink

    The intracellular tacrolimus concentration in CD3+ T lymphocytes is proposed to be a better representative of the active component of tacrolimus than the whole blood concentration. However, intracellular measurements are complicated. Therefore, the aim of this study was to describe the relationship between intracellular and whole blood tacrolimus concentrations in a population pharmacokinetic model. Twenty‐eight de novo kidney transplant recipients, treated with a once‐daily oral extended‐release tacrolimus formulation, were followed during the first‐month post‐transplantation. Additional whole blood and intracellular tacrolimus concentrations were measured at day 6 ± 1 (pre‐dose, 4 and 8 hours post‐dose) and day 14 ± 3 (pre‐dose) post‐transplantation. Pharmacokinetic analysis was performed using nonlinear mixed effects modeling software (NONMEM). The ratio between intracellular (n = 109) and whole blood (n = 248) concentrations was best described by a two‐compartment whole blood model with an additional intracellular compartment without mass transfer from the central compartment. The ratio remained stable over time. Prednisolone dose influenced the absorption rate of tacrolimus, while hemoglobin, CYP3A4*22 allele carrier, and CYP3A5 expresser status were associated with the oral clearance of tacrolimus (P‐value < 0.001). Furthermore, the intracellular tacrolimus concentrations were correlated with the intracellular production of interleukin‐2 (P‐value 0.015). The intracellular tacrolimus concentration can be predicted from a measured whole blood concentration using this model, without the need for repeated intracellular measurements. This knowledge is particularly important when the intracellular concentration is ready to be implemented into clinical practice, to overcome the complexities of cell isolation and analytical methods.


  • Open Access

    Modelling changes in the pharmacokinetics of tacrolimus during pregnancy after kidney transplantation: A retrospective cohort study

    by Maaike R. Schagen, Asiye Nur Ulu, Marith I. Francke, Jacqueline van de Wetering, Marleen C. van Buren, Sam Schoenmakers, Maja Matic, Ron H. N. van Schaik, Dennis A. Hesselink, Brenda C. M. de Winter

    Aims: Pregnancy after kidney transplantation is realistic but immunosuppressants should be continued to prevent rejection. Tacrolimus is safe during pregnancy and is routinely dosed based on whole‐blood predose concentrations. However, maintaining these concentrations is complicated as physiological changes during pregnancy affect tacrolimus pharmacokinetics. The aim of this study was to describe tacrolimus pharmacokinetics throughout pregnancy and explain the changes by investigating covariates in a population pharmacokinetic model.Methods: Data of pregnant women using a twice‐daily tacrolimus formulation following kidney transplantation were retrospectively collected from 6 months before conception, throughout gestation and up to 6 months postpartum. Pharmacokinetic analysis was performed using nonlinear mixed effects modelling. Demographic, clinical and genetic parameters were evaluated as covariates. The final model was evaluated using goodness‐of‐fit plots, visual predictive checks and a bootstrap analysis.Results: A total of 260 whole‐blood tacrolimus predose concentrations from 14 pregnant kidney transplant recipients were included. Clearance increased during pregnancy from 34.5 to 41.7 L/h, by 15, 19 and 21% in the first, second and third trimester, respectively, compared to prior to pregnancy. This indicates a required increase in the tacrolimus dose by the same percentage to maintain the prepregnancy concentration. Haematocrit and gestational age were negatively correlated with tacrolimus clearance (P ≤ 0.01), explaining 18% of interindividual and 85% of interoccasion variability in oral clearance.Conclusions: Tacrolimus clearance increases during pregnancy, resulting in decreased exposure to tacrolimus, which is explained by gestational age and haematocrit. To maintain prepregnancy target whole‐blood tacrolimus predose concentrations during pregnancy, increasing the dose is required.


  • Open Access

    Individualized dosing algorithms for tacrolimus in kidney transplant recipients: current status and unmet needs

    by Maaike R. Schagen, Helena Volarevic, Marith I. Francke, Sebastiaan D.T. Sassen, Marlies E.J. Reinders, Dennis A. Hesselink, Brenda C.M. de Winter

    Tacrolimus is a potent immunosuppressive drug with many side effects including nephrotoxicity and post-transplant diabetes mellitus. To limit its toxicity, therapeutic drug monitoring (TDM) is performed. However, tacrolimus' pharmacokinetics are highly variable within and between individuals, which complicates their clinical management. Despite TDM, many kidney transplant recipients will experience under- or overexposure to tacrolimus. Therefore, dosing algorithms have been developed to limit the time a patient is exposed to off-target concentrations. Tacrolimus starting dose algorithms and models for follow-up doses developed and/or tested since 2015, encompassing both adult and pediatric populations. Literature was searched in different databases, i.e. Embase, PubMed, Web of Science, Cochrane Register, and Google Scholar, from inception to February 2023. Many algorithms have been developed, but few have been prospectively evaluated. These performed better than bodyweight-based starting doses, regarding the time a patient is exposed to off-target tacrolimus concentrations. No benefit in reduced tacrolimus toxicity has yet been observed. Most algorithms were developed from small datasets, contained only a few tacrolimus concentrations per person, and were not externally validated. Moreover, other matrices should be considered which might better correlate with tacrolimus toxicity than the whole-blood concentration, e.g. unbound plasma or intra-lymphocytic tacrolimus concentrations.